AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) have received FDA priority review status for their antibody-drug conjugate datopotamab deruxtecan.

Datopotamab deruxtecan has previously been granted breakthrough therapy designation by the FDA for this patient population.

Zhitong FinanceJan 14 21:20

AstraZeneca (AZN) Receives a Buy From Barclays

TipRanksJan 14 14:05 · Ratings

AstraZeneca's Dato-DXd BLA Accepted for Priority Review

Seeking AlphaJan 13 23:08

Why Astrazeneca (AZN) Is a Top Value Stock for the Long-Term

Yahoo FinanceJan 13 22:40

AstraZeneca (AZN) Receives a Buy From Goldman Sachs

TipRanksJan 13 17:56 · Ratings

FDA Grants Priority Review to Daiichi Sankyo and AstraZeneca's Datopotamab Deruxtecan for Advanced Lung Cancer Treatment

BenzingaJan 13 15:14